🔗 Share this article

As the US proceeds with unprecedented revisions to its vaccine recommendations, a particular individual appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by expressing skepticism about Covid shots during the global health crisis and has concentrated on alleged fatalities after Covid vaccination in her brief position at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Immunization Schedule

Agency leaders planned to unveil major revisions to the childhood vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, sources say – a substantial departure that would place the US out of alignment with many the international standard with insufficient data for benefit. The planned update has been delayed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to speak at the gathering. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth appointee to run the office this calendar year.

A New Direction at the Agency

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics centers as Høeg and Prasad consolidate power at the agency – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

The new acting director has frequently advocated for discontinuing specific childhood shot schedules in the US in order to be more in line with Denmark's approach, a society with nationalized medicine and a citizenry approximately the population of Wisconsin’s.

To date statements, she has persisted in emphasizing on vaccines – typically the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Qualifications

The appointee has no obvious track record in pharmaceutical research, approval processes or management, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for running the drug-regulation department, said Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in leading a major agency. She is not an expert in drug approvals.”

Previous commissioners of the center would “understand legal statutes and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she has not acquired the sort of resume that previous people who headed CBER have had.”

CDER has an immense portfolio at the FDA, she pointed out.

“Many people just focuses on the innovative therapies, but the generic program authorizes thousands of generic medications. There’s a biosimilars division, non-prescription drug unit and other areas, and every single one need to be looked after,” Dr. Woodcock said. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a significant management component to the position, which manages in excess of 5,000 employees. “It is a massive management job, if you do it right,” she said.

Response and Contentious Programs

In response to inquiries about Dr. Høeg's qualifications and whether this appointment signifies increased cooperation among agency officials on vaccines, a spokesperson responded that the “concerns stem from flawed presumptions”.

“Her resume is consistent with the duties of her role,” the official explained, citing the months Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg takes over the agency head's controversial priority voucher program, a disputed rapid drug-approval program that reportedly worried her predecessors. “By what process are these drugs being selected for this fast-track system? Who takes the decisions?” Howard asked. “There’s a lot of confidentiality occurring at the agency right now.”

Overall, he remarked, “the agency seems to be moving towards laxer regulations of all drugs, with the exception of vaccines.”

Established Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a clearer, if troubling, history, critics said. She authored a research paper using unconfirmed volunteer-provided data to estimate the incidence of myocarditis following COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are more dangerous than they are.

Included in her “policy goals” for the current federal leadership featured altering guidelines for new vaccines and discontinuing “optional” vaccines, she said post-election on a podcast. At the FDA, Dr. Høeg has allegedly proposed excluding teenage boys from getting COVID-19 vaccines.

“She’s an all-around dogmatist who starts off with her conclusions and works backwards to accommodate the data in a extremely disingenuous, fraudulent way,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|